Schrödinger’s Second Quarter: A Co‑Scientist’s Revenue Playbook, Powered by ACV, Milestones, and a One‑Off Windfall

Quarterly snapshot: ACV climbs, software moves to hosted, and Ajax sparks a milestone

Schrödinger, Inc. (SDGR) delivered a second‑quarter release that reads like a lab notebook with a few financial annotations. Annualized contract value (ACV) came in at $29.6 million for the quarter, marking a 27% year‑over‑year increase and bringing the trailing four‑quarter ACV to about $208 million. That implies customers are renewing and expanding at a pace that the company will happily pretend is durable—an important signal for the durability of its “predict‑first” approach to molecular discovery.

On the revenue front, total revenue reached $58.9 million, up 8% from the prior year. The segment story is nuanced. Software revenue was $32.5 million, down 10% year over year as Schrödinger accelerates its move to hosted software licensing. The company notes hosted revenue comprised 47% of software revenue and 30% on a trailing four‑quarter basis, underscoring a deliberate tilt toward hosted licensing as a longer‑term growth and margin strategy.

Drug discovery revenue rose to $23.0 million, a meaningful jump from $13.9 million a year ago, driven in part by a $10 million collaboration milestone tied to Ajax Therapeutics. Contribution revenue stood at $3.4 million, down from $4.8 million, with timing of revenue from Gates Foundation projects cited as a factor. Net income posted a modest $6.0 million profit for the quarter, reversing a $43.2 million loss a year earlier, while operating expenses declined 6% to $74.0 million.

Another notable line item: other income, driven by fair value changes in investments and interest income/expense, totaled $48.9 million, largely fueled by a gain connected to Eli Lilly and Ajax Therapeutics’ acquisition closure. In plain terms: a big one‑off tailwind boosted the bottom line, masking a lot of the ongoing operating dynamics. The company also reported cash, cash equivalents, restricted cash and marketable securities of $418.8 million.

A note on presentation and what it means for earnings quality

Schrödinger emphasizes a segmentation where contribution revenue and cost of revenue are reported separately from software and drug discovery lines. The restatement of prior periods to conform to this presentation is meant to improve year‑over‑year comparability, but it also complicates straight‑line trend analysis. For investors tracking EPS, the lack of a reported EPS figure in this excerpt makes the immediate earnings surprise calculus ambiguous. Still, the swing in net income, aided by a non‑operating gain, highlights how much of the bottom line can be influenced by one‑offs and investment gains rather than operating progress alone.

Outlook and revenue forecast: a path to steadier growth or another phase of acceleration?

Looking ahead, Schrödinger provided a 2026 financial and operational outlook as of August 5, 2026. The company set a revenue forecast path built on ACV expansion, expecting ACV to range from $218 million to $228 million, representing 10%–15% growth over 2025. The drug discovery revenue forecast was raised to a range of $65 million to $75 million, up from a prior expectation of $55 million to $65 million, driven by the Ajax milestone momentum and related collaborations.

In other words, the company is signaling that a more predictable base of revenue—via ACV and hosted software licensing—could provide a foundation for upside, while milestone‑driven collaboration revenue adds a volatile but potentially meaningful kicker. The absence of a formal EPS forecast in this update suggests that investors should weigh the trajectory of ACV growth and hosted licensing adoption as the primary drivers of long‑term profitability, with GAAP earnings vulnerable to one‑offs and non‑operating gains.

Takeaways: what this might portend for Schrödinger and its peers

First, the ACV expansion is a real data point. A 27% quarterly rise, with a trailing ACV of about $208 million, signals durable demand for Schrödinger’s predictive chemistry platform and its agentic co‑scientist Bunsen. The move toward hosted licensing within the software business aligns with broader software‑as‑a‑service (SaaS) dynamics: shorter renewal cycles, recurring revenue, and potentially improving gross margins over time as the hosted model scales. The 71% gross margin on software is healthy, and if the hosted mix continues to rise, the software line could become more of a margin engine than a cost center in the medium term.

Second, the Ajax‑Lilly angle is a reminder that a lot of Schrödinger’s headline volatility still comes from strategic collaborations and M&A‑adjacent events. The $10 million milestone from Ajax Therapeutics boosted drug discovery revenue, while a gain from Eli Lilly’s Ajax acquisition contributed largely to the quarterly bottom line. In practice, this means the stock will likely trade on pipeline milestones and exits as much as on quarterly operating progress. For sector peers, those dynamics underscore the importance of collaboration cadence and the timing of milestone receipts in shaping quarterly earnings quality.

Third, the lack of an explicit EPS figure in the release invites a broader commentary on earnings quality. If a market is fixated on EPS consensus, Schrödinger’s current quarter shows that meaningful net income can emerge from a favorable mix of operating performance and one‑off gains rather than a pure operating beat. That’s not a negative so much as a reminder that earnings surprises can be a function of accounting inputs as well as business momentum. Investors may want to test whether the company can convert the current top‑line momentum and the hosted licensing transition into sustained EPS growth, independent of non‑operating windfalls.

Finally, the guidance points to a dual engine: (1) a rise in ACV and a gradual shift to hosted software licensing, and (2) collaboration revenue tied to marquee partnerships like Ajax. For peers in the AI‑driven drug discovery arena, the message is clear: customers appear willing to engage in longer, value‑based contracts if the product delivers measurable predictive accuracy and reduces discovery risk. The trick for the sector will be managing the transition from one‑off milestones and equity gains to a durable, recurring revenue core that can support a more stable earnings trajectory and credible EPS growth over time.

Sector implications: what might change for the AI‑driven drug discovery space

Schrödinger’s results sit at an interesting cross‑section of software licensing dynamics and advanced life‑science collaborations. If the company sustains its hosted licensing ramp and the Ajax/Lilly momentum continues to yield recurring milestones or long‑term collaboration revenues, peers could see a shift in valuation favoring revenue quality and visibility over pure topline growth. Investors may increasingly reward companies with clear ACV trajectories and a credible path to ARR‑like metrics, even if quarterly profits remain uneven due to one‑time items.

From a strategic standpoint, Schrödinger’s emphasis on a “predict‑first” workflow and the deployment of its agentic AI co‑scientist suggests a broader industry push toward AI‑augmented discovery as a standard operating model. If this programmatic approach translates into faster discovery timelines and higher experimental yield, the sector could witness an acceleration of collaboration deals and a re‑weighting of R&D budgets toward long‑term, performance‑based payment structures.